Analyst Price Targets — KYTX
Latest News for KYTX
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the following upcoming conferences:
Kyverna Therapeutics, Inc. remains a compelling Buy as it advances mivocabtagene autoleucel for autoimmune diseases, targeting first approval in stiff person syndrome. Updated KYSA-8 trial data show all 26 patients remained off chronic immunotherapies at 16 weeks, with 81% mobility improvement, supporting regulatory momentum. Rolling BLA submission for miv-cel is underway, with anticipated completion in late 2026…
FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy's potential across neuroimmunology
Kyverna Therapeutics remains a 'Strong Buy' as miv-cel advances in SPS, gMG, and refractory RA with robust clinical data. Rolling BLA submission for miv-cel in SPS is underway, targeting completion by Q4 2026, supported by positive phase 2 KYSA-8 results. The manufacturing agreement with ElevateBio secures supply for miv-cel, supporting U.S. and global commercialization and future indications.
EMERYVILLE, Calif., and WALTHAM, Mass.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KYTX.
U.S. House Trading
No House trades found for KYTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.